Fig. 1From: Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)Flow chart of participant enrollment, allocation, and analysis. FAS full analysis setBack to article page